Virtual screening for finding inhibitor against the main protease of SARS-Cov-2 from the FDA-approved drugs database
2022 International Conference on Biomedical and Intelligent Systems, IC-BIS 2022
; 12458, 2022.
Article
in English
| Scopus | ID: covidwho-2193346
ABSTRACT
At the end of 2019,a new coronavirus suddenly broke out all over the world.To date, there is still no targeted medicine available for the treatment of this disease. Vaccineis essential for controlling the epidemicofSARS-CoV-2. But the effective ofvaccine was reduced because of the SARS-CoV-2constant mutation. It is gratifying that scientistuncover theinfection mechanisms of the SARS-CoV-2. The main protease of SARS-CoV-2 is highly conserved and plays an important role of the life cycle of virus. Therefore, we executed virtual screening on the FDA-approved database and hoped to find a potential candidate against the main protease. As a result, we obtained eight available active compounds derived from the database through molecular dynamics simulations. As antiviral treatment candidates, the drugs can also be used to clinical emergencies. © 2022 SPIE. All rights reserved.
Full text:
Available
Collection:
Databases of international organizations
Database:
Scopus
Language:
English
Journal:
2022 International Conference on Biomedical and Intelligent Systems, IC-BIS 2022
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS